PVPaola Vidal-Montal

Paola Vidal-Montal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paola Vidal-Montal has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Disease Activity: Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis Remission and Low Disease Activity

    by Joan M. Nolla, Lidia Valencia-Muntalà, Diego Benavent, Paola Vidal-Montal, Laura Berbel-Arcobé, Montserrat Roig-Kim, Martí Aguilar-Coll, Mònica Cubells, Aina Fabregat, Javier Narváez, et al.

    Background/Objectives: Remission and low disease activity (LDA) are established treatment targets in rheumatoid arthritis (RA), but they may not imply normalization of patient-perceived disease burden. Fatigue and health-related quality of life (HRQoL) provide complementary measures of patient-perceived health beyond inflammatory disease activity. Moreover, disease activity states defined by the Disease Activity Score in 28 joints (DAS28) and the Routine Assessment of Patient Index Data 3 (RAPID3) may be associated with different patient-reported outcome profiles. We aimed to compare fatigue and HRQoL in patients with RA classified as being in remission or LDA with those of controls and to assess agreement between DAS28 and RAPID3 classifications. Methods: We conducted a cross-sectional comparative study with a control group within the BELL-RA-LIFE cohort including 275 patients with RA aged >50 years and 300 controls with a comparable age and sex distribution. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and HRQoL using the Short Form-12 Physical (PCS) and Mental Component Summary (MCS) scores. Patients were classified independently according to DAS28 and RAPID3. Multivariable linear regression models adjusted for age, sex, body mass index, and hemoglobin were used to estimate differences versus controls. Agreement between DAS28 and RAPID3 was assessed using weighted Cohen’s kappa. Results: No statistically significant differences from controls were detected in FACIT-F or MCS scores among patients in DAS28 remission, although PCS scores were lower (adjusted difference −3.37, 95% CI −5.56 to −1.18; nominal p = 0.003; Holm-adjusted p = 0.033). DAS28-defined LDA was associated with greater fatigue and poorer PCS scores, although these differences did not remain statistically significant after Holm adjustment (adjusted p = 0.256 and p = 0.100, respectively), whereas MCS scores remained significantly lower (adjusted difference −5.15, 95% CI −8.14 to −2.15; nominal p = 0.001; adjusted p = 0.012). In patients in RAPID3 remission, PCS and MCS scores did not differ significantly from controls, while FACIT-F scores were higher; this difference did not remain statistically significant after Holm adjustment (adjusted p = 0.117); no statistically significant differences were detected for RAPID3-defined LDA across the three outcomes. Overall agreement between DAS28 and RAPID3 was limited (quadratic weighted κ = 0.35, 95% CI 0.26–0.44), with no significant difference between women and men (κ = 0.30 and 0.41, respectively; Δκ = 0.11, 95% CI −0.12 to 0.31; p = 0.34). RAPID3 more frequently classified patients into higher disease activity categories than DAS28 in 80.6% of discordant classifications. Conclusions: Remission and LDA in RA were associated with different residual health burdens when assessed using DAS28. Patients in DAS28 remission had significantly lower physical HRQoL than controls, while those in DAS28-defined LDA had significantly poorer mental HRQoL. No statistically significant differences in fatigue or HRQoL were observed for RAPID3-defined remission or LDA. Agreement between DAS28 and RAPID3 was limited and directional, with RAPID3 more frequently assigning patients to higher disease activity categories. These findings support the complementary assessment of inflammatory disease activity and patient-reported health in patients with RA.

  • Characterizing systemic lupus erythematosus associated myocarditis: From rare clinical disease to subclinical involvement

    by Javier Narváez, Laia de Daniel-Bisbe, Olga Capdevila, Francesca Mitjavila, Eduard Claver, Maria Pilar Mañas-Jimenez, Mònica Cubells, Aina Fabregat, Montserrat Roig-Kim, Martí Aguilar-Coll, et al.

  • Open Access

    Beyond glomeruli: interstitial fibrosis and tubular atrophy predict poor renal outcomes in lupus nephritis

    by Paola Vidal-Montal, Javier Narvaez, Francesca Mitjavila, Xavier Fulladosa, Olga Capdevila, Joan Torras, Montserrat Gomà, Joan M Nolla

    To evaluate the prevalence, associated factors, and prognostic performance of NIH activity index–defined interstitial inflammation (NIH-TII) and interstitial fibrosis and tubular atrophy (IFTA) in lupus nephritis (LN). This retrospective cohort study analyzed 195 renal biopsy episodes from 135 LN patients. Tubulointerstitial lesions were graded according to histopathological severity. NIH-TII was assessed semiquantitatively using the interstitial inflammation component of the modified NIH activity index. Among 195 renal biopsies, class IV LN was most frequent (49.2%). Tubulointerstitial involvement was present in 74.3% of cases, with isolated NIH-TII in 14.4%, isolated IFTA in 15.9%, and both in 44.1%. Moderate-to-severe NIH-TII and IFTA were observed in 11.3% and 15.9% of biopsies, respectively. Patients with moderate-to-severe NIH-TII were older, had worse renal function, and more frequently exhibited moderate-to-severe IFTA. Moderate-to-severe IFTA was associated with older age, longer SLE duration, prior LN episodes, higher chronicity index, and impaired renal function, and was strongly associated with non-renal response and ESRD progression. In multivariable logistic regression, prior LN episodes (OR 8.4) and moderate-to-severe IFTA (OR 4.92) predicted non-renal response. In multivariable Cox regression, prior LN episodes (HR 8.55), moderate-to-severe IFTA (HR 8.93), and thrombotic microangiopathy (HR 12.99) predicted ESRD progression. Longitudinal analyses showed frequent progression of IFTA over time with increasing chronicity index. Moderate-to-severe IFTA was a strong predictor of renal non-response and ESRD progression. TII defined according to the NIH activity index, which does not include systematic assessment of tubulitis or total cortical inflammatory burden, was not independently associated with outcomes. The online version contains supplementary material available at 10.1186/s13075-026-03799-6.


  • Open Access

    Health-Related Quality of Life in Older Adults with Rheumatoid Arthritis: A Sex-Specific Case–Control Analysis of Physical and Mental Health Domains

    by Joan M. Nolla, Diego Benavent, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Paola Vidal-Montal, Judith Palacios-Olid, Montserrat Roig-Kim, Martí Aguilar-Coll, Javier Narváez, Carmen Gómez-Vaquero

    Background: The impact of rheumatoid arthritis (RA) on health-related quality of life (HRQoL) in older adults remains incompletely characterized, particularly regarding sex-specific patterns and the relative contribution of physical and mental health domains in later life. Methods: We conducted an observational cross-sectional case–control analysis including adults aged ≥65 years. A total of 180 patients with RA (65.6% women) were compared with 195 age- and sex-matched control subjects. HRQoL was assessed using the Short Form-12 (SF-12) questionnaire, generating Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Analyses were stratified by sex. Associations between HRQoL domains and clinical variables were examined using correlation analyses and sex-specific multivariable linear regression models. Effect sizes (Cohen’s d) were calculated to quantify the magnitude of between-group differences. Results: Women with RA showed significantly lower SF-12 physical (PCS) and mental (MCS) component scores than men with RA, indicating a greater impairment in overall HRQoL. Women also exhibited higher functional disability, as assessed by the Health Assessment Questionnaire (HAQ), and higher disease activity, as assessed by DAS28. In sex-stratified case–control comparisons, men with RA showed lower SF-12 PCS scores, while MCS scores were comparable to those of the age-matched male controls. In contrast, women with RA exhibited significantly lower PCS and MCS scores compared to age-matched female controls. In multivariable analyses, distinct sex-specific patterns were observed. In women with RA, HAQ emerged as the only independent determinant of PCS, whereas DAS28 was the sole independent determinant of MCS. In men with RA, PCS was independently associated with DAS28, whereas MCS was independently associated with HAQ. Effect size analyses indicated consistently small impairments in both physical and mental HRQoL domains in women, whereas in men, the impact was small and largely confined to the physical domain. Conclusions: In older adults with RA, HRQoL impairment is sex-dependent and domain-specific, with women experiencing a more pronounced and generalized reduction in both physical and mental health compared with men. Sex-specific differences in the relative contribution of disease activity and functional disability highlight the need for a differentiated interpretation of patient-reported outcomes in this population. A domain-specific and sex-aware assessment of HRQoL may enhance the clinical evaluation of older patients and provide a more comprehensive understanding of disease burden beyond inflammatory activity alone.


  • Open Access

    Nutritional Risk in Older Adults with Rheumatoid Arthritis: Sex-Specific Patterns and Clinical Implications of the Prognostic Nutritional Index

    by Joan M. Nolla, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Diego Benavent, Paola Vidal-Montal, Pol Maymó-Paituvi, Montserrat Roig-Kim, Martí Aguilar-Coll, Javier Narváez, Carmen Gómez-Vaquero

    Background/Objectives: Nutritional risk is increasingly recognized as a relevant but under-assessed dimension of rheumatoid arthritis (RA), particularly in older adults managed in outpatient settings. Simple nutritional indices such as the Prognostic Nutritional Index (PNI) may help identify individuals at increased nutritional risk beyond conventional disease activity measures. This study aimed to characterize nutritional risk in older adults with RA using the Prognostic Nutritional Index, explore sex-specific patterns, and identify clinical associations of PNI variability, with complementary analyses focusing on high nutritional risk. Methods: We conducted an observational cross-sectional study including 275 consecutive adults aged ≥50 years with RA attending routine follow-up at a tertiary rheumatology clinic. Nutritional risk was assessed using the PNI, calculated from serum albumin and total lymphocyte count, and analyzed primarily as a continuous variable and secondarily using established cut-off values. Clinical characteristics, inflammatory markers, body mass index, laboratory parameters, and patient-reported outcomes were recorded. Analyses were stratified by sex. Multivariable linear regression models were used to identify factors associated with PNI variability, and complementary logistic regression analyses were performed to explore factors independently associated with high nutritional risk (PNI < 40). Results: More than half of the cohort (53.3%) exhibited PNI values compatible with nutritional risk. Men showed lower PNI values than women, with a markedly greater prevalence of high nutritional risk (18.0% vs. 5.0%, p < 0.001). In multivariable linear regression analyses, higher C-reactive protein levels and increasing age were independently associated with lower PNI values, whereas sex was not an independent determinant of PNI. In multivariable logistic regression analyses, increasing age and male sex were independently associated with high nutritional risk. In multivariable linear regression models restricted to men, hemoglobin emerged as the principal independent correlate of PNI. In complementary logistic regression analyses focusing on high nutritional risk (PNI < 40), hemoglobin remained the sole independent predictor (OR = 0.94, 95% CI 0.91–0.98; p < 0.01), supporting a robust association with clinically relevant nutritional risk. Conclusions: Nutritional risk assessed by the PNI is common among older adults with RA. Although sex does not independently determine PNI as a continuous measure, male sex is associated with severe nutritional risk. The PNI captures a clinically relevant dimension of disease burden that extends beyond joint inflammation and traditional activity indices, supporting its use as a pragmatic nutritional screening tool in routine rheumatology practice.


  • Open Access

    Health-Related Quality of Life in Older Adults with Rheumatoid Arthritis: A Sex-Specific Case-Control Analysis of Physical and Mental Health Domains

    by Joan M. Nolla, Diego Benavent, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Paola Vidal-Montal, Judith Palacios-Olid, Montserrat Roig-Kim, Martí Aguilar-Coll, Javier Narváez, Carmen Gómez-Vaquero

    Background: The impact of rheumatoid arthritis (RA) on health-related quality of life (HRQoL) in older adults remains incompletely characterized, particularly regarding sex-specific patterns and the relative contribution of physical and mental health domains in later life. Methods: We conducted an observational cross-sectional case–control analysis including adults aged ≥65 years. A total of 180 patients with RA (65.6% women) were compared with 195 age- and sex-matched control subjects. HRQoL was assessed using the Short Form-12 (SF-12) questionnaire, generating Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Analyses were stratified by sex. Associations between HRQoL domains and clinical variables were examined using correlation analyses and sex-specific multivariable linear regression models. Effect sizes (Cohen’s d) were calculated to quantify the magnitude of between-group differences. Results: Women with RA showed significantly lower SF-12 physical (PCS) and mental (MCS) component scores than men with RA, indicating a greater impairment in overall HRQoL. Women also exhibited higher functional disability, as assessed by the Health Assessment Questionnaire (HAQ), and higher disease activity, as assessed by DAS28. In sex-stratified case–control comparisons, men with RA showed SF-12 PCS and MCS scores comparable to those of age-matched male controls. In contrast, women with RA exhibited significantly lower PCS and MCS scores compared with age-matched female controls. In multivariable analyses, distinct sex-specific patterns were observed. In women with RA, HAQ emerged as the only independent determinant of PCS, whereas DAS28 was the sole independent determinant of MCS. In men with RA, PCS was independently associated with DAS28, whereas MCS was independently associated with HAQ. Effect size analyses indicated small-to-moderate impairments in both physical and mental HRQoL domains in women, whereas in men the impact was small and largely confined to the physical domain. Conclusions: In older adults with RA, HRQoL impairment is sex-dependent and domain-specific, with women experiencing a more pronounced and generalized reduction in both physical and mental health compared with men. Sex-specific differences in the relative contribution of disease activity and functional disability highlight the need for a differentiated interpretation of patient-reported outcomes in this population. A domain-specific and sex-aware assessment of HRQoL may enhance the clinical evaluation of older patients and provide a more comprehensive understanding of disease burden beyond inflammatory activity alone.


  • Top Cited Papers
    Open Access

    Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

    by Paola Vidal-Montal, Aina Fabregat, Irene Altabás-González, José María Pego-Reigosa, Andrea Hernández-Martínez, Iñigo Rua-Figueroa, Tarek Salman-Monte, Clara Moriano, Beatriz Tejera Segura, Paloma Vela, et al.

    Objective: To evaluate the efficacy, safety and predictive factors of belimumab (BEL)-based triple therapy in proliferative lupus nephritis (LN) in real-world settings. Methods: We conducted a multicentre, retrospective study including patients with proliferative LN (new-onset or relapsing) who initiated BEL within 6 months of a renal flare, in combination with standard-of-care. Results: 49 patients were included (mean age 37 years; 85.7% female; 67.3% Caucasian). The median time from renal flare to BEL initiation was 1 month (IQR 0–3). By 12 months, 67.3% achieved complete renal response (CRR), 75.5% primary efficacy renal response (PERR) and 83.7% at least partial renal response. Median proteinuria declined from 2.7 g/day to 0.49 g/day, with parallel improvement in estimated glomerular filtration rate (71 to 78 mL/min/1.73 m²). Patients with baseline proteinuria <3 g/day achieved significantly higher CRR (78.1% vs 47.1%; p=0.027) and PERR (84.4% vs 58.8%; p=0.048) rates. The mean glucocorticoid (GC) dose decreased from 31.7 mg/day at baseline to 3.5 mg/day at 12 months, and 26.1% of patients achieved complete GC withdrawal. Extrarenal disease activity was present in 81.6% of patients at baseline, predominantly articular and mucocutaneous, with clinically meaningful improvement in 80% during follow-up. At 12 months, 40.8% met remission by Definition Of Remission In Systemic Lupus Erythematosus (DORIS) criteria and 46.9% attained Lupus Low Disease Activity State (LLDAS). Renal treatment failure occurred in 16.3% and renal relapse in 4.1%. Adverse events were mild, and no serious BEL-related events were observed. Conclusion: BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.


  • Open Access

    Nutritional Risk in Older Adults with Rheumatoid Arthritis: Sex-Specific Patterns and Clinical Implications of the Prognostic Nutritional Index

    by Joan M. Nolla, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Diego Benavent, Paola Vidal-Montal, Pol Maymó-Paituví, Montserrat Roig-Kim, Martí Aguilar-Coll, Javier Narváez, Carmen Gómez-Vaquero

    Background/Objectives Nutritional risk is increasingly recognized as a relevant but under-assessed dimension of rheumatoid arthritis (RA), particularly in older adults managed in outpatient settings. Simple nutritional indices such as the Prognostic Nutritional Index (PNI) may help identify individuals at increased nutritional risk beyond conventional disease activity measures. This study aimed to characterize nutritional risk in older adults with RA using the Prognostic Nutritional Index, explore sex-specific patterns, and identify clinical associations of PNI variability, with complementary analyses focusing on high nutritional risk. Methods We conducted an observational cross-sectional study including 275 consecutive adults aged ≥50 years with RA attending routine follow-up at a tertiary rheumatology clinic. Nutritional risk was assessed using the PNI, calculated from serum albumin and total lymphocyte count, and analyzed primarily as a continuous variable and secondarily using established cut-off values. Clinical characteristics, inflammatory markers, body mass index, laboratory parameters, and patient-reported outcomes were recorded. Analyses were stratified by sex. Multivariable linear regression models were used to identify factors associated with PNI variability, and complementary logistic regression analyses were performed to explore factors independently associated with high nutritional risk (PNI < 40). Results More than half of the cohort (53.3%) exhibited PNI values compatible with nutritional risk. Men showed significantly lower PNI values than women, with a higher frequency of nutritional risk (61.5% vs. 49.7%, p < 0.01) and a markedly greater prevalence of high nutritional risk (18.0% vs. 5.0%, p < 0.001). Sex-specific association patterns were observed. In women, PNI showed only a weak inverse association with age. In contrast, in men, lower PNI values were associated with higher inflammatory burden, greater disease activity, lower body mass index, poorer mental health–related quality of life, and lower hemoglobin levels. In multivariable linear regression models restricted to men, hemoglobin emerged as the principal independent correlate of PNI. In complementary logistic regression analyses focusing on high nutritional risk (PNI < 40), hemoglobin remained the sole independent predictor (OR = 0.94, 95% CI 0.91–0.98; p < 0.01), supporting a robust association with clinically relevant nutritional risk. Conclusions Nutritional risk assessed by the PNI is common among older adults with RA and displays pronounced sex-specific patterns, with men showing a substantially higher burden of nutritional risk. The PNI captures a clinically relevant dimension of disease burden that extends beyond joint inflammation and traditional activity indices, supporting its use as a pragmatic nutritional screening tool in routine rheumatology practice.


  • Open Access

    SARC-F as a Screening Tool in Rheumatoid Arthritis: Real-World Burden of Sarcopenia Risk, Sex Differences, and Clinical Correlates

    by Joan M. Nolla, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Diego Benavent, Paola Vidal-Montal, Martí Aguilar-Coll, Montserrat Roig-Kim, Javier Narváez, Carmen Gómez-Vaquero

    Background/Objectives: Sarcopenia is now recognized as a frequent and disabling accompaniment of rheumatoid arthritis (RA), although structured screening approaches are still rarely applied in everyday practice. The SARC-F questionnaire offers a simple, validated, patient-reported tool for sarcopenia screening, but its performance in RA remains largely unexplored. We aimed to evaluate the burden of sarcopenia risk, defined by abnormal SARC-F scores (≥4), and its clinical correlates in RA compared with age- and sex-matched controls. Methods: We conducted an observational case–control study including 275 RA patients (69.5% women) aged >50 years and 300 matched controls. Clinical, laboratory, and patient-reported outcomes were recorded. Sarcopenia risk was assessed using SARC-F (cutoff ≥ 4). RA patients also underwent grip strength and gait speed testing. Multivariable regression analyses were used to identify independent correlates of abnormal SARC-F results. Results: A SARC-F score ≥ 4 was observed in 26.9% of RA patients. Compared with controls, the burden was significantly higher in women with RA (34.0% vs. 24.7%, p < 0.05) but not in men (10.7% vs. 15.0%). Within the RA cohort, abnormal SARC-F was independently associated with female sex (OR 3.14, 95% CI 1.24–7.95) and higher RAPID3 scores (OR 1.25, 95% CI 1.18–1.33). More than half of RA patients exhibited low grip strength, with partial overlap with SARC-F findings. Conclusions: The SARC-F questionnaire revealed a notable burden of sarcopenia risk in RA, particularly among women. Combined with simple grip strength testing, it offers a feasible, low-cost approach to case finding, directly applicable in routine rheumatology practice. Incorporating this strategy may enhance recognition and management of sarcopenia in RA.


  • Open Access

    SARC-F as a Screening Tool in Rheumatoid Arthritis: Real-World Burden of Sarcopenia Risk, Sex Differences, and Clinical Correlates

    by Joan M. Nolla, Lidia Valencia-Muntalà, Laura Berbel-Arcobé, Diego Benavent, Paola Vidal-Montal, Martí Aguilar-Coll, Montserrat Roig-Kim, Javier Narváez, Carmen Gómez-Vaquero

    Background/Objectives: Sarcopenia is increasingly recognized as a relevant comorbidity in rheumatoid arthritis (RA), yet systematic case finding is rarely implemented in clinical practice. The SARC-F questionnaire offers a simple, validated, patient-reported tool for sarcopenia screening, but its performance in RA remains largely unexplored. We aimed to evaluate the burden of sarcopenia risk, defined by abnormal SARC-F scores (≥4), and its clinical correlates in RA compared with age- and sex-matched controls. Methods: We conducted an observational case–control study including 275 RA patients (69.5% women) aged >50 years and 300 matched controls. Clinical, laboratory, and patient-reported outcomes were recorded. Sarcopenia risk was assessed using SARC-F (cutoff ≥4). RA patients also underwent grip strength and gait speed testing. Multivariable regression analyses were used to identify independent correlates of abnormal SARC-F results. Results: A SARC-F score ≥4 was observed in 28.8% of RA patients. Compared with controls, the burden was significantly higher in women with RA (34.0% vs. 24.7%, p < 0.05) but not in men (10.7% vs. 15.0%). Within the RA cohort, abnormal SARC-F was independently associated with female sex (OR 3.14, 95% CI 1.24–7.95) and higher RAPID3 scores (OR 1.25, 95% CI 1.18–1.33). More than half of RA patients exhibited low grip strength, with partial overlap with SARC-F findings. Conclusions: The SARC-F questionnaire revealed a notable burden of sarcopenia risk in RA, particularly among women. Combined with simple grip strength testing, it offers a feasible, low-cost approach to case finding, directly applicable in routine rheumatology practice. Incorporating this strategy may enhance recognition and management of sarcopenia in RA.